Host: Heather Wakelee, MD, FASCO

Guest: Lyudmila Bazhenova, MD

We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.